A Phase 1 interventional study of N-803 in Relapsed or Refractory Multiple Myeloma, sponsored by Altor BioScience. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-26.
Sponsored by Altor BioScience (part of ImmunityBio, Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,168 studies in Multiple Myeloma with a site in United States — 275 open to participants now, 503 under way, 66 of them phase 3. Multiple Myeloma · United States.
Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 1,355th largest by enrollment of the 1,901 interventional ones that give a count, is one of 79 that started in 2014, is one of 559 in phase 1, and was the 1,104th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →275 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
PrECOG, LLC. · Sites in United States
Ages 18–79
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,168 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 853 · Phase 2 1,052 · Phase 3 191 · Phase 4 14
First in 1975; this study’s year is marked. 79 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 36 across the 1,901 interventional studies, 154 across the 167 observational. Of the 1,537 that completed or were terminated, 725 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
689 of 2,168 have an industry lead sponsor. The 10 most frequent:
This study is registered under Altor BioScience, one of the names counted as ImmunityBio, Inc.. Under that name alone:
Altor BioScience is the lead sponsor of 15 studies on the registry; none are open to participants now.
ImmunityBio, Inc. has 2 studies filed under Multiple Myeloma — fewer than ten, so there is no comparison to draw.
156 of the studies in Multiple Myeloma with a site in United States that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT01863550Phase 3ECOG-ACRIN Cancer Research GroupBortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | 2026-12-31 |
| NCT03823534Phase 3St. Louis UniversityPost-Op Pain Control for Prophylactic Intramedullary Nailing. | 2026-12-31 |
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
Add all 156 to your calendar (.ics) → With an account.
Among the 2,168 studies in Multiple Myeloma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapsed or refractory multiple myeloma.
The purpose of this study is to evaluate the safety, determine the Maximum Tolerated Dose (MTD) or the Minimum Efficacious Dose (MED) and characterize the immunogenicity and pharmacokinetic profile of N-803 in treated patients. The effect of N-803 on the peripheral absolute lymphocyte counts and white blood cell counts, the number and phenotype of peripheral blood T (total and subsets) and NK cells will be evaluated. The anti-tumor responses of N-803 will also be assessed in this trial.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
This study's enrollment of 19 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Altor BioScience is the lead sponsor of 15 studies on the registry; none are open to participants now.
First submitted before Altor BioScience became part of ImmunityBio, Inc..
Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
ENTRY CRITERIA:
DISEASE CHARACTERISTICS:
Confirmed diagnosis of multiple myeloma after treatment with at least two different previous regimens.
as defined by at least one of the following:
PRIOR/CONCURRENT THERAPY:
PATIENT CHARACTERISTICS:
Performance Status
Bone Marrow Reserve
Renal Function
Hepatic Function
Cardiovascular
Pulmonary
Other
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: N-803
Biological: N-803
Biological: N-803
Biological: N-803
Biological: N-803
Biological: N-803
Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
Number of Participants With Treatment Emergent Adverse Events
For phase I - Number of Participants with Treatment Emergent Adverse Events that occur or worsen after the first dose of study treatment.
Time frame: 24 weeks
Disease Response Rate of Treated Patients
CR- negative SIFE and UIFE, disappearance of any soft tissue plasmacytomas, and \< or = to 5% plasma cells in bone marrow VGPR - either + SIFE and UIFE and - SPEP and UPEP or reduction in serum M-protein \> or = to 90% and urine m-protein level \<100mg per 24h PR - if measurable serum an urine m-protein them reduction of serum m-protein by \>=50% and reduction in 24h urinary m protein by \>=90% or to \<200mg per 24h if unmeasurable serum and urine m-protein then \>= 50% decrease in the difference between involve and uninvolved FLC levels If unmeasurable serum and urine m-protein and serum FLC assay then \>= 50% reduction in plasma cells, provide baseline bone marrow plasma cell percentage was \>=30% In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required PD - defined via International Myeloma Working Group uniform response criteria: disease progression SD - not meeting criteria for CR, VGPR, PR or PD
Time frame: Starts at Week 11 - 12 and Week 23 - 24
Characterization of the Pharmacokinetic Profile - Half-life (t½)
Half-life (t½) - The period of time required for the concentration or amount of drug in the body to be reduced by one-half.
Time frame: PK timepoint up to 72 hours +/- 6 hours
Characterization of the Pharmacokinetic Profile - Time of the Observed Maximum Concentration (Tmax)
time of the observed maximum concentration (Tmax)
Time frame: PK timepoint up to 72 hours +/- 6 hours
Characterization of the Pharmacokinetic Profile - Maximum Observed Concentration (Cmax)
maximum observed concentration (Cmax)
Time frame: PK timepoint up to 72 hours +/- 6 hours
Characterization of the Pharmacokinetic Profile - Area Under the Plasma Concentration Curve
Area under the plasma concentration curve from time 0 through the last measurable concentration (AUC0-t). PK samples were obtained from the start of treatment until 72 hours. The AUC0-168 and AUC0-inf were calculated with noncompartmental pharmacokinetic analysis equations.
Time frame: Samples were collected and the AUC was determined at 24 hours and at time t (last measurable concentration). The AUC was calculated for 168 hours and time to infinity.
Characterization of the Pharmacokinetic Profile - Clearance (CL)
Clearance (CL)
Time frame: PK timepoint up to 72 hours +/- 6 hours
Characterization of the Pharmacokinetic Profile - Vss Volume of Distribution at Steady State
Vss Volume of distribution at steady state is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration
Time frame: PK timepoint up to 72 hours +/- 6 hours
Immunogenicity - Anti-drug Antibody (ADA)
Number of patients with a positive Anti-drug Antibody (ADA) result
Time frame: From Baseline up to Week 12
Characterization of the Pharmacokinetic Profile - Apparent (Extravascular) Clearance (CL/F)
Apparent (Extravascular) Clearance (CL/F)
Time frame: PK timepoint up to 72 hours +/- 6 hours
Characterization of the Pharmacokinetic Profile - Apparent (Extravascular) Volume of Distribution (Vz/F)
Apparent volume of distribution is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration
Time frame: PK timepoint up to 72 hours +/- 6 hours
| Milestone | Cohort 1: N-803 - IV 1 ug/kg | Cohort 2: N-803 - IV 3 ug/kg | Cohort 3: N-803 - IV 6 ug/kg | Cohort 4: N-803 - IV 10 ug/kg | Cohort 5: N-803 - SQ 10 ug/kg | Cohort 6: N-803 - SQ 15 ug/kg | Cohort 7: N-803 - SQ 20 ug/kg |
|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 4 | 3 | 0 |
| Completed | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Not completed | 3 | 2 | 3 | 2 | 4 | 3 | 0 |
| Withdrew: Progressive disease | 3 | 2 | 2 | 1 | 4 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
For phase I - Number of Participants with Treatment Emergent Adverse Events that occur or worsen after the first dose of study treatment.
| Participants | Cohort 1: N-803 - IV 1 ug/kg | Cohort 2: N-803 - IV 3 ug/kg | Cohort 3: N-803 - IV 6 ug/kg | Cohort 4: N-803 - IV 10 ug/kg | Cohort 5: N-803 - SQ 10 ug/kg | Cohort 6: N-803 - SQ 15 ug/kg |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events | 3 | 3 | 3 | 3 | 4 | 3 |
CR- negative SIFE and UIFE, disappearance of any soft tissue plasmacytomas, and \< or = to 5% plasma cells in bone marrow VGPR - either + SIFE and UIFE and - SPEP and UPEP or reduction in serum M-protein \> or = to 90% and urine m-protein level \<100mg per 24h PR - if measurable serum an urine m-protein them reduction of serum m-protein by \>=50% and reduction in 24h urinary m protein by \>=90% or to \<200mg per 24h if unmeasurable serum and urine m-protein then \>= 50% decrease in the difference between involve and uninvolved FLC levels If unmeasurable serum and urine m-protein and serum FLC assay then \>= 50% reduction in plasma cells, provide baseline bone marrow plasma cell percentage was \>=30% In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required PD - defined via International Myeloma Working Group uniform response criteria: disease progression SD - not meeting criteria for CR, VGPR, PR or PD
| Participants | Cohort 1: N-803 - IV 1 ug/kg | Cohort 2: N-803 - IV 3 ug/kg | Cohort 3: N-803 - IV 6 ug/kg | Cohort 4: N-803 - IV 10 ug/kg | Cohort 5: N-803 - SQ 10 ug/kg | Cohort 6: N-803 - SQ 15 ug/kg |
|---|---|---|---|---|---|---|
| Stable Disease | 0 | 1 | 1 | 1 | 0 | 1 |
| Progressive Disease | 3 | 2 | 1 | 2 | 2 | 2 |
| Not available to evaluate | 0 | 0 | 1 | 0 | 1 | 0 |
Half-life (t½) - The period of time required for the concentration or amount of drug in the body to be reduced by one-half.
| Hours | Cohort 1: N-803 - IV 1 ug/kg | Cohort 2: N-803 - IV 3 ug/kg | Cohort 3: N-803 - IV 6 ug/kg | Cohort 4: N-803 - IV 10 ug/kg | Cohort 5: N-803 - SQ 10 ug/kg | Cohort 6: N-803 - SQ 15 ug/kg |
|---|---|---|---|---|---|---|
| Characterization of the Pharmacokinetic Profile - Half-life (t½) | 0.773 (0.734 to 0.826) | 2.41 (2.40 to 2.41) | 2.21 (2.02 to 2.39) | 3.07 (2.33 to 4.14) | — | 35.3 (35.3 to 35.3) |
time of the observed maximum concentration (Tmax)
| Hours | Cohort 1: N-803 - IV 1 ug/kg | Cohort 2: N-803 - IV 3 ug/kg | Cohort 3: N-803 - IV 6 ug/kg | Cohort 4: N-803 - IV 10 ug/kg | Cohort 5: N-803 - SQ 10 ug/kg | Cohort 6: N-803 - SQ 15 ug/kg |
|---|---|---|---|---|---|---|
| Characterization of the Pharmacokinetic Profile - Time of the Observed Maximum Concentration (Tmax) | 0.583 (0.5 to 0.683) | 0.583 (0.5 to 0.633) | 0.65 (0.633 to 0.717) | 0.667 (0.667 to 2.33) | 33.1 (4.22 to 65.9) | 6.0 (2.0 to 20.3) |
maximum observed concentration (Cmax)
| ng/mL | Cohort 1: N-803 - IV 1 ug/kg | Cohort 2: N-803 - IV 3 ug/kg | Cohort 3: N-803 - IV 6 ug/kg | Cohort 4: N-803 - IV 10 ug/kg | Cohort 5: N-803 - SQ 10 ug/kg | Cohort 6: N-803 - SQ 15 ug/kg |
|---|---|---|---|---|---|---|
| Characterization of the Pharmacokinetic Profile - Maximum Observed Concentration (Cmax) | 8.45 ± 1.78 | 42.7 ± 1.76 | 142 ± 26.6 | 144 ± 70.7 | 0.383 ± 0.111 | 1.69 ± 1.41 |
Area under the plasma concentration curve from time 0 through the last measurable concentration (AUC0-t). PK samples were obtained from the start of treatment until 72 hours. The AUC0-168 and AUC0-inf were calculated with noncompartmental pharmacokinetic analysis equations.
| hr x ng/mL | Cohort 1: N-803 - IV 1 ug/kg | Cohort 2: N-803 - IV 3 ug/kg | Cohort 3: N-803 - IV 6 ug/kg | Cohort 4: N-803 - IV 10 ug/kg | Cohort 5: N-803 - SQ 10 ug/kg | Cohort 6: N-803 - SQ 15 ug/kg |
|---|---|---|---|---|---|---|
| AUC0-t | 10.5 (7.58 to 13.7) | 129 (105 to 166) | 634 (439 to 845) | 808 (577 to 1200) | 13.6 (6.00 to 21.2) | 60.4 (9.61 to 135) |
| AUC0-24 | 10.6 (7.62 to 13.8) | 141 (116 to 166) | 731 (618 to 845) | 811 (577 to 1220) | 5.01 (2.91 to 6.69) | 31.1 (11.7 to 65.5) |
| AUC0-168 | 10.6 (7.62 to 13.8) | 141 (116 to 166) | 732 (618 to 846) | 813 (578 to 1220) | — | 31.4 (31.4 to 31.4) |
| AUC0-inf | 10.6 (7.61 to 13.7) | 141 (116 to 166) | 732 (618 to 846) | 814 (578 to 1220) | — | 32.5 (32.5 to 32.5) |
Clearance (CL)
| mL/hr/kg | Cohort 1: N-803 - IV 1 ug/kg | Cohort 2: N-803 - IV 3 ug/kg | Cohort 3: N-803 - IV 6 ug/kg | Cohort 4: N-803 - IV 10 ug/kg |
|---|---|---|---|---|
| Characterization of the Pharmacokinetic Profile - Clearance (CL) | 99.9 (72.7 to 131) | 22.0 (18.1 to 25.9) | 8.4 (7.09 to 9.71) | 13.7 (8.20 to 17.3) |
Vss Volume of distribution at steady state is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration
| mL/kg | Cohort 1: N-803 - IV 1 ug/kg | Cohort 2: N-803 - IV 3 ug/kg | Cohort 3: N-803 - IV 6 ug/kg | Cohort 4: N-803 - IV 10 ug/kg |
|---|---|---|---|---|
| Characterization of the Pharmacokinetic Profile - Vss Volume of Distribution at Steady State | 126 (101 to 159) | 71.8 (65.9 to 77.8) | 34.0 (30.2 to 37.8) | 62.8 (39.0 to 78.0) |
Number of patients with a positive Anti-drug Antibody (ADA) result
| Participants | Cohort 1: N-803 - IV 1 ug/kg | Cohort 2: N-803 - IV 3 ug/kg | Cohort 3: N-803 - IV 6 ug/kg | Cohort 4: N-803 - IV 10 ug/kg | Cohort 5: N-803 - SQ 10 ug/kg | Cohort 6: N-803 - SQ 15 ug/kg |
|---|---|---|---|---|---|---|
| Immunogenicity - Anti-drug Antibody (ADA) | 0 | 0 | 0 | 0 | 0 | 0 |
Apparent (Extravascular) Clearance (CL/F)
| mL/hr/kg | Cohort 5: N-803 - SQ 10 ug/kg | Cohort 6: N-803 - SQ 15 ug/kg |
|---|---|---|
| Characterization of the Pharmacokinetic Profile - Apparent (Extravascular) Clearance (CL/F) | — | 462 (462 to 462) |
Apparent volume of distribution is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration
| mL/kg | Cohort 5: N-803 - SQ 10 ug/kg | Cohort 6: N-803 - SQ 15 ug/kg |
|---|---|---|
| Characterization of the Pharmacokinetic Profile - Apparent (Extravascular) Volume of Distribution (Vz/F) | — | 23500 (23500 to 23500) |
Collected over Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: N-803 - IV 1 ug/kg | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Cohort 2: N-803 - IV 3 ug/kg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort 3: N-803 - IV 6 ug/kg | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort 4: N-803 - IV 10 ug/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Cohort 5: N-803 - SQ 10 ug/kg | 3/4 (75%) | 3/4 (75%) | 4/4 (100%) |
| Cohort 6: N-803 - SQ 15 ug/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Cohort 7: N-803 - SQ 20 ug/kg | — | — | — |
| Event | Cohort 1: N-803 - IV 1 ug/kg | Cohort 2: N-803 - IV 3 ug/kg | Cohort 3: N-803 - IV 6 ug/kg | Cohort 4: N-803 - IV 10 ug/kg | Cohort 5: N-803 - SQ 10 ug/kg | Cohort 6: N-803 - SQ 15 ug/kg | Cohort 7: N-803 - SQ 20 ug/kg |
|---|---|---|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 1/3 | 0/3 | 0/3 | 3/4 | 0/3 | — |
| PyrexiaGeneral disorders | 2/3 | 0/3 | 0/3 | 0/3 | 1/4 | 0/3 | — |
| DehydrationMetabolism and nutrition disorders | 1/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/3 | — |
| AtaxiaNervous system disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/4 | 0/3 | — |
| Cardiac arrestCardiac disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/4 | 0/3 | — |
| HypercalcaemiaMetabolism and nutrition disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/4 | 0/3 | — |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/4 | 0/3 | — |
| Event | Cohort 1: N-803 - IV 1 ug/kg | Cohort 2: N-803 - IV 3 ug/kg | Cohort 3: N-803 - IV 6 ug/kg | Cohort 4: N-803 - IV 10 ug/kg | Cohort 5: N-803 - SQ 10 ug/kg | Cohort 6: N-803 - SQ 15 ug/kg | Cohort 7: N-803 - SQ 20 ug/kg |
|---|---|---|---|---|---|---|---|
| ChillsGeneral disorders | 0/3 | 3/3 | 0/3 | 2/3 | 1/4 | 2/3 | — |
| Injection site reactionGeneral disorders | 0/3 | 0/3 | 0/3 | 0/3 | 4/4 | 0/3 | — |
| PyrexiaGeneral disorders | 2/3 | 3/3 | 1/3 | 2/3 | 3/4 | 3/3 | — |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 1/3 | 0/3 | 0/3 | 4/4 | 0/3 | — |
| NauseaGastrointestinal disorders | 1/3 | 1/3 | 1/3 | 1/3 | 3/4 | 0/3 | — |
| Lymphocyte count decreasedInfections and infestations | 1/3 | 1/3 | 0/3 | 2/3 | 3/4 | 1/3 | — |
| AnaemiaBlood and lymphatic system disorders | 2/3 | 1/3 | 1/3 | 2/3 | 2/4 | 0/3 | — |
| ConstipationGastrointestinal disorders | 1/3 | 2/3 | 1/3 | 0/3 | 1/4 | 0/3 | — |
| FatigueGeneral disorders | 1/3 | 0/3 | 2/3 | 2/3 | 1/4 | 1/3 | — |
| HypersensitivityImmune system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 2/3 | — |
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
| Age, Continuous(years) | Cohort 1: ALT-803 - IV 1 ug/kg | Cohort 2: ALT-803 - IV 3 ug/kg | Cohort 3: ALT-803 - IV 6 ug/kg | Cohort 4: ALT-803 - IV 10 ug/kg | Cohort 5: ALT-803 - SQ 10 ug/kg | Cohort 6: ALT-803 - SQ 15 ug/kg | Cohort 7: ALT-803 - SQ 20 ug/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 71.7 ± 4.16 | 59.3 ± 6.66 | 63.7 ± 6.35 | 61.7 ± 12.1 | 49.8 ± 22.63 | 67.0 ± 5.0 | — | 61.5 ± 13.05 |
| Sex: Female, Male(Participants) | Cohort 1: ALT-803 - IV 1 ug/kg | Cohort 2: ALT-803 - IV 3 ug/kg | Cohort 3: ALT-803 - IV 6 ug/kg | Cohort 4: ALT-803 - IV 10 ug/kg | Cohort 5: ALT-803 - SQ 10 ug/kg | Cohort 6: ALT-803 - SQ 15 ug/kg | Cohort 7: ALT-803 - SQ 20 ug/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 2 | 0 | 3 | 2 | 0 | 2 | 0 | 9 |
| Male | 1 | 3 | 0 | 1 | 4 | 1 | 0 | 10 |
| Race (NIH/OMB)(Participants) | Cohort 1: ALT-803 - IV 1 ug/kg | Cohort 2: ALT-803 - IV 3 ug/kg | Cohort 3: ALT-803 - IV 6 ug/kg | Cohort 4: ALT-803 - IV 10 ug/kg | Cohort 5: ALT-803 - SQ 10 ug/kg | Cohort 6: ALT-803 - SQ 15 ug/kg | Cohort 7: ALT-803 - SQ 20 ug/kg | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| White | 3 | 3 | 2 | 3 | 3 | 3 | 0 | 17 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Patients with Relapsed or Refractory Multiple Myeloma(Participants) | Cohort 1: ALT-803 - IV 1 ug/kg | Cohort 2: ALT-803 - IV 3 ug/kg | Cohort 3: ALT-803 - IV 6 ug/kg | Cohort 4: ALT-803 - IV 10 ug/kg | Cohort 5: ALT-803 - SQ 10 ug/kg | Cohort 6: ALT-803 - SQ 15 ug/kg | Cohort 7: ALT-803 - SQ 20 ug/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Count of participants | 3 | 3 | 3 | 3 | 4 | 3 | 0 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2014 to primary completion in Jun 2018, 44 months.
Results were first posted in Sep 2024, 6 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nogapendekin alfa inbakicept